Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0C3VI
|
||||
| Former ID |
DNC003709
|
||||
| Drug Name |
PD-167341
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C33H46N4O5
|
||||
| Canonical SMILES |
CC(C)CC(C(=O)NC(CC1=CC=C(C=C1)OC(=O)C2=CC=CC=C2)C(=O)NC<br />(C)(C)C)NC(=O)N3CCCCCC3
|
||||
| InChI |
1S/C33H46N4O5/c1-23(2)21-27(35-32(41)37-19-11-6-7-12-20-37)29(38)34-28(30(39)36-33(3,4)5)22-24-15-17-26(18-16-24)42-31(40)25-13-9-8-10-14-25/h8-10,13-18,23,27-28H,6-7,11-12,19-22H2,1-5H3,(H,34,38)(H,35,41)(H,36,39)/t27-,28-/m0/s1
|
||||
| InChIKey |
RASCVEWVRJPMSU-NSOVKSMOSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Voltage-dependent N-type calcium channel | Target Info | Inhibitor | [1] | |
| KEGG Pathway | MAPK signaling pathway | ||||
| Calcium signaling pathway | |||||
| Synaptic vesicle cycle | |||||
| Retrograde endocannabinoid signaling | |||||
| Cholinergic synapse | |||||
| Serotonergic synapse | |||||
| GABAergic synapse | |||||
| Dopaminergic synapse | |||||
| Taste transduction | |||||
| Type II diabetes mellitus | |||||
| Morphine addiction | |||||
| Nicotine addiction | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Ionotropic glutamate receptor pathway | |||||
| Metabotropic glutamate receptor group III pathway | |||||
| Metabotropic glutamate receptor group II pathway | |||||
| Thyrotropin-releasing hormone receptor signaling pathway | |||||
| Endogenous cannabinoid signaling | |||||
| GABA-B receptor II signaling | |||||
| Reactome | Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels | ||||
| WikiPathways | Calcium Regulation in the Cardiac Cell | ||||
| Synaptic Vesicle Pathway | |||||
| References | |||||
| REF 1 | J Med Chem. 1999 Oct 7;42(20):4239-49.Synthesis of a series of 4-benzyloxyaniline analogues as neuronal N-type calcium channel blockers with improved anticonvulsant and analgesic properties. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.